INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis

John F. Woolley, Keyue Chen, Golam T. Saffi, Gizem Esra Genç, Daniel K.c. Lee, Irakli Dzneladze, Ruijuan He, Jonathan Tak-Sum Chow, Martino Gabra, Meong Hi Son, Ché M.p. Melo, Candaice A. Newell, Aobo He, Erwin M. Schoof, Stephanie Z. Xie, Emily M. Mangialardi, Max Kotlyar, Ayesha Rashid, Miki S. Gams, Jean Vacher, Cynthia J. Guidos, Igor Jurišica, John E. Dick, Roberto J. Botelho, Mark D. Minden, Leonardo SalmenabioRxiv 2021 · DOI

TL;DR

This paper uncovers a novel pathway where the protein INPP4B drives lysosome biogenesis, promoting "stemness" in leukemia stem cells (LSCs) and hindering their differentiation. This discovery explains why high INPP4B levels correlate with poor AML prognosis and suggests INPP4B as a potential therapeutic target and biomarker for aggressive AML.

What Problem Does This Paper Address?

Acute Myeloid Leukemia (AML) is a complex blood cancer characterized by a hierarchy of cells, with leukemic stem cells (LSCs) at the apex. These LSCs possess "stemness" properties like self-renewal and multipotent differentiation, which are crucial for maintaining the leukemia and driving relapse, especially after treatment. While LSCs are known to be resistant to chemotherapy, the precise molecular mechanisms governing their stemness and survival remain largely unclear. Previous work hinted that INPP4B, a lipid phosphatase, is overexpressed in a subset of AML patients and linked to poor outcomes. This study aims to elucidate the specific roles of INPP4B in leukemogenesis, particularly its connection to LSC maintenance and differentiation.

Methods

The researchers employed a multi-pronged approach:

  • In vivo mouse models: They generated and studied mice with Inpp4b-deficient leukemias (using Inpp4b knockout mice) to assess disease latency, leukemia-initiating potential, and differentiation status.
  • Cell line models: They used OCI-AML2 and MLL-AF9 leukemia cell lines to investigate the effects of INPP4B overexpression and knockdown on lysosomal function, gene expression, and cellular phenotypes.
  • Molecular analyses: Techniques like RNA sequencing (RNA-seq) were used to identify differentially expressed genes in Inpp4b-deficient leukemias. Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) analysis were employed to pinpoint perturbed biological pathways, with a particular focus on lysosome-related pathways.
  • Functional assays: Lysotracker Red staining was used to assess lysosome levels, Magic Red and DQ-BSA-Green assays measured lysosomal proteolytic activity, and colony-forming unit (CFU) assays evaluated the impact of lysosomal inhibition on leukemia cell growth and differentiation.
  • Human AML datasets: Publicly available gene expression data from AML patient cohorts were analyzed to correlate INPP4B expression with stemness signatures and lysosomal gene expression.

Datasets

The study utilized several publicly available human AML patient datasets for gene expression analysis, including:

  • The Cancer Genome Atlas (TCGA)-LAML dataset.
  • Datasets from Verhaak, Valk, Herold, Klein, Metzeler, Wouters, and Balgobind.

These datasets were used to identify enriched gene ontologies and pathways associated with INPP4B expression levels in AML patients.

Key Insights and Ideas

  • INPP4B as a "stemness" driver: The most striking finding is that INPP4B actively promotes leukemic "stemness" by driving lysosome biogenesis. This is a novel mechanism linking a specific protein to the maintenance of LSC properties.
  • Lysosomes are central to INPP4B's role: The research strongly implicates lysosomes as the key cellular machinery through which INPP4B exerts its effects. INPP4B appears to regulate lysosomal gene expression, content, and function.
  • Disrupting lysosomes hinders leukemia: Inhibiting lysosomal function, either by Inpp4b deficiency or pharmacological agents, leads to reduced leukemia-initiating potential and promotes differentiation of leukemic cells. This suggests lysosomes are critical for LSC survival and self-renewal.
  • INPP4B's prognostic significance: The consistent association of high INPP4B expression with poor AML prognosis across multiple datasets underscores its clinical relevance.
  • TFEB independence: Surprisingly, INPP4B promotes lysosomal biogenesis without affecting the nuclear translocation of TFEB, a known master regulator of lysosomal genes. This points to a potentially novel regulatory mechanism.

Key Results

  • Inpp4b-deficient MLL-AF9 leukemias in mice showed increased disease latency and reduced leukemia-initiating capacity.
  • Inpp4b-deficient leukemias exhibited a more differentiated phenotype, with altered cell surface marker expression.
  • RNA-seq analysis revealed that lysosome-related gene sets were significantly perturbed in Inpp4b-deficient leukemias.
  • INPP4B overexpression in AML cell lines led to increased lysosomal content and proteolytic activity.
  • Inhibition of lysosomal function with Lys05 reduced colony-forming capacity of AML cells in an Inpp4b-dependent manner.
  • High INPP4B expression in human AML patients was significantly associated with leukemic stemness signatures and lysosomal gene signatures.

Limitations and Future Work

  • Therapeutic feasibility: The authors note that INPP4B inhibition is not currently feasible, highlighting the need for further research into developing such strategies.
  • Mechanism of TFEB independence: The exact molecular mechanism by which INPP4B promotes lysosomal gene expression without influencing TFEB nuclear translocation remains to be elucidated. Further studies are required to understand this interaction.
  • Drug target validation: While INPP4B and lysosomal pathways are identified as potential therapeutic targets, further validation and development of specific inhibitors are necessary.
  • Biomarker utility: The study suggests INPP4B as a biomarker for aggressive AML and response to lysosomal inhibition. Future work could focus on validating this in larger clinical cohorts.

Summary updated

Abstract

Abstract Signaling pathways that control vital features of leukemic stem cells including multipotency, self-renewal, clonal expansion and quiescence remain unclear. Emerging studies illustrate critical roles for lysosomes in hematopoietic and leukemic stem cell fate. By investigating consequences of INPP4B alterations in AML, we have discovered its role in driving leukemic ‘stemness’. We observed that INPP4B is highly expressed leukemic stem cell populations and Inpp4b -deficeint leukemias demonstrate increased disease latency, reduced leukemia initiating potential which is associated with a differentiated leukemic phenotype. Molecular analyses show that Inpp4b -deficient leukemias have compromised lysosomal gene expression, lysosomal content, and lysosomal activity. Our discovery of a novel pathway linking INPP4B, lysosomal biogenesis and leukemic stemness, provides a mechanism to explain the association of high INPP4B expression with poor AML prognosis, and highlights novel patient stratification strategies and LSC-specific leukemic therapies. Key Points Our findings highlight a novel pathway linking INPP4B, lysosomal function and leukemic stemness that explains the prognostic role of INPP4B in AML. Our data reveal the utility of INPP4B as a biomarker of aggressive AML and provide a rationale to explore INPP4B and its associated function in lysosome biology as novel strategies to target LSC and AML
BibTeX
@misc{woolley2021inpp,
  author = {John F. Woolley and Keyue Chen and Golam T. Saffi and Gizem Esra Genç and Daniel K.C. Lee and Irakli Dzneladze and Ruijuan He and Jonathan Tak-Sum Chow and Martino Gabra and Meong Hi Son and Ché M.P. Melo and Candaice A. Newell and Aobo He and Erwin M. Schoof and Stephanie Z. Xie and Emily M. Mangialardi and Max Kotlyar and Ayesha Rashid and Miki S. Gams and Jean Vacher and Cynthia J. Guidos and Igor Jurišica and John E. Dick and Roberto J. Botelho and Mark D. Minden and Leonardo Salmena},
  title = {{INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis}},
  year = {2021},
  doi = {10.1101/2021.03.25.437029},
  howpublished = {bioRxiv},
}
Figure